Biological resistance of hydroxychloroquine for Plasmodium vivax malaria in the Republic of Korea

American Journal of Tropical Medicine and Hygiene

Volumn 81, Issue 4, 2009, Pages 600-604

  Sei, Won Lee ^b   Lee, Minhee ^c   Dae, Dong Lee ^d   Kim, Changsoo ^e   Kim, Yeon Joo ^f   Kim, Jung Yeon ^g   Green, Michael D ^h   Klein, Terry A ⁱ   Heung, Chul Kim ^d   Nettey, Henry ^h   Dong, Hoon Ko ^b   Kim, Hyungsuk ^j   Park, Inho ^a  

^a Armed Forces Seoul Hospital   (South Korea)

^b Armed Forces Capital Hospital   (South Korea)

^c Armed Forces Ildong Hospital   (South Korea)

^d Armed Forces Yangju Hospitial ^*  (United States)

^e Yonsei University College of Medicine   (South Korea)

^f Korea Centers for Disease Control and Prevention   (South Korea)

^g Korea National Institute of Health   (South Korea)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ Force Health Protection   (United States)

^j Armed Forces Byuck Je Hospital   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CHEMOPROPHYLAXIS; FEVER; HUMAN; KOREA; MAJOR CLINICAL STUDY; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA;

ADULT; ANIMALS; ANTIMALARIALS; CHLOROQUINE; DRUG RESISTANCE; HUMANS; HYDROXYCHLOROQUINE; KOREA; MALARIA, VIVAX; MALE; MIDDLE AGED; PLASMODIUM VIVAX; PRIMAQUINE; YOUNG ADULT;

PLASMODIUM VIVAX;

EID: 70349730095     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2009.09-0102     Document Type: Article

References (35)

1. Coatney GR, 1963. Pitfalls in a discovery: the chronicle of chloroquine. Am J Trop Med Hyg 12: 121-128.
2. Organization WH, 2001. The Use of Antimalarial Drugs. Report of a WHO Informal Consultation. Report WHO/CDS/RBM/2001.33. Geneva: Switzerland.
3. Baird JK, Basri H, Purnomo, Bangs MJ, Subianto B, Patchen LC, Hoffman SL, 1991. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg 44: 547-552. (Pubitemid 26335969)
4. Rieckmann KH, Davis DR, Hutton DC, 1989. Plasmodium vivax resistance to chloroquine? Lancet 2: 1183-1184.
5. Oh MD, Shin H, Shin D, Kim U, Lee S, Kim N, Choi MH, Chai JY, Choe K, 2001. Clinical features of vivax malaria. Am J Trop Med Hyg 65: 143-146.
6. Feighner BH, Pak SI, Novakoski WL, Kelsey LL, Strickman D, 1998. Reemergence of Plasmodium vivax malaria in the republic of Korea. Emerg Infect Dis 4: 295-297. (Pubitemid 28311218)
7. Park JW, Klein TA, Lee HC, Pacha LA, Ryu SH, Yeom JS, Moon SH, Kim TS, Chai JY, Oh MD, Choe KW, 2003. Vivax malaria: a continuing health threat to the Republic of Korea. Am J Trop Med Hyg 69: 159-167.
8. Kim HC, Pacha LA, Lee WJ, Lee JK, Gaydos JC, Sames WJ, Lee HCS, Bradley K, Jeung GG, Tobler SK, Klein TA, 2009. Malaria in the Republic of Korea, 1993-2007. Variable related to reemergence and persistence of Plasmodium vivax among Korean populations and US Forces Korea. Mil Med 174: (in press).
9. Klein TA, Pacha LA, Lee HCS, Kim HC, Lee WJ, Lee JK, Jeung GG, Sames WJ, Gaydos JC, 2009. Plasmodium vivax malaria among U.S. Forces Korea in the Republic of Korea, 1993-2007. Mil Med 174: 412-418.
10. Yeom JS, Ryu SH, Oh S, Choi DH, Song KJ, Oh YH, Lee JH, Kim YA, Ahn SY, Yang HY, Cha JE, Park JW, 2005. Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army. J Korean Med Sci 20: 707-712. (Pubitemid 41587225)
11. Berliner RW, Earle DP, Taggart JV, Zubrod CG, Welch WJ, Conan NJ, Bauman E, Scudder ST, Shannon JA, 1948. Studies on the chemotherapy of the human malarias. VI. The physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline. J Clin Invest 27: 98-107.
12. Baird JK, 2004. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 48: 4075-4083.
13. Han ET, Lee DH, Park KD, Seok WS, Kim YS, Tsuboi T, Shin EH, Chai JY, 2006. Reemerging vivax malaria: changing patterns of annual incidence and control programs in the Republic of Korea. Korean J Parasitol 44: 285-294.
14. Schuurkamp GJ, Spicer PE, Kereu RK, Bulungol PK, Rieckmann KH, 1992. Chloroquine-resistant Plasmodium vivax in Papua New Guinea. Trans R Soc Trop Med Hyg 86: 121-122.
15. Bergqvist Y, Domeij-Nyberg B, 1983. Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma. J Chromatogr 272: 137-148. (Pubitemid 13164612)
16. Gustafsson LL, Walker O, Alvan G, Beermann B, Estevez F, Gleisner L, Lindstrom B, Sjoqvist F, 1983. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol 15: 471-479.
17. Taylor WR, Doan HN, Nguyen DT, Tran TU, Fryauff DJ, Gomez-Saladin E, Kain KC, Le DC, Baird JK, 2000. Assessing drug sensitivity of Plasmodium vivax to halofantrine or choroquine in southern, central Vietnam using an extended 28-day in vivo test and polymerase chain reaction genotyping. Am J Trop Med Hyg 62: 693-697.
18. Murphy GS, Basri H, Purnomo, Andersen EM, Bangs MJ, Mount DL, Gorden J, Lal AA, Purwokusumo AR, Harjosuwarno S, 1993. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet 341: 96-100. (Pubitemid 23028126)
19. Baird JK, Leksana B, Masbar S, Suradi, Sutanihardja MA, Fryauff DJ, Subianto B, 1997. Whole blood chloroquine concentrations with Plasmodium vivax infection in Irian Jaya, Indonesia. Am J Trop Med Hyg 56: 618-620. (Pubitemid 27318582)
20. Baird JK, Fryauff DJ, Basri H, Bangs MJ, Subianto B, Wiady I, Purnomo, Leksana B, Masbar S, Richie TL 1995. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg 52: 479-484.
21. Fryauff DJ, Baird JK, Basri H, Sumawinata I, Purnomo, Richie TL, Ohrt CK, Mouzin E, Church CJ, Richards AL, 1995. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 346: 1190-1193.
22. Sumawinata IW, Bernadeta, Leksana B, Sutamihardja A, Purnomo, Subianto B, Sekartuti, Fryauff DJ, Baird JK, 2003. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 68: 416-420. (Pubitemid 38230641)
23. Baird JK, Wiady I, Fryauff DJ, Sutanihardja MA, Leksana B, Widjaya H, Kysdarmanto, Subianto B, 1997. In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. Am J Trop Med Hyg 56: 627-631.
24. Hugosson E, Tarimo D, Troye-Blomberg M, Montgomery SM, Premji Z, Bjorkman A, 2003. Antipyretic, parasitologic, and immunologic effects of combining sulfadoxine/pyrimethamine with chloroquine or paracetamol for treating uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 69: 366-371. (Pubitemid 38248269)
25. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, Wignall FS, Hoffman SL, 1997. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 56: 621-626. (Pubitemid 27318583)
26. Lim CS, Kim YK, Lee KN, Kim MJ, Kim KH, Kim DS, Strickman D, 1999. Response to chloroquine of Plasmodium vivax among South Korean soldiers. Ann Trop Med Parasitol 93: 565-568. (Pubitemid 29438127)
27. Goller JL, Jolley D, Ringwald P, Biggs BA, 2007. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Am J Trop Med Hyg 76: 203-207. (Pubitemid 351627764)
28. Signorini L, Matteelli A, Castelnuovo F, Castelli F, Oladeji O, Carosi G, 1996. Short report: primaquine-tolerant Plasmodium vivax in an Italian traveler from Guatemala. Am J Trop Med Hyg 55: 472-473. (Pubitemid 26392706)
29. Rombo L, Bjorkman A, Sego E, Ericsson O, 1986. Whole blood concentrations of chloroquine and desethylchloroquine during and after treatment of adult patients infected with Plasmodium vivax, P. ovale, or P. malariae. Trans R Soc Trop Med Hyg 80: 763-766. (Pubitemid 17222301)
30. Touze JE, Debonne JM, Boutin JP. 2007. Current situation and future perspectives for malaria prophylaxis among travellers and military personnel. Bull Acad Natl Med 191: 1293-1302, discussion 1302-1303.
31. Sonmez A, Harlak A, Kilic S, Polat Z, Hayat L, Keskin O, Dogru T, Yilmaz MI, Acikel CH, Kocar IH, 2005. The efficacy and tolerability of doxycycline and mefloquine in malaria prophylaxis of the ISAF troops in Afghanistan. J Infect 51: 253-258. (Pubitemid 41554834)
32. Kofoed K, Petersen E, 2003. The efficacy of chemoprophylaxis against malaria with chloroquine plus proguanil, mefloquine, and atovaquone plus proguanil in travelers from Denmark. J Travel Med 10: 150-154. (Pubitemid 36712318)
33. Kain KC, Harrington MA, Tennyson S, Keystone JS, 1998. Imported malaria: prospective analysis of problems in diagnosis and management. Clin Infect Dis 27: 142-149. (Pubitemid 28334433)
34. Rombo L, Bergqvist Y, Hellgren U, 1987. Chloroquine and desethylchloroquine concentrations during regular long-term malaria prophylaxis. Bull World Health Organ 65: 879-883. (Pubitemid 18067167)
35. Baird JK, Basri H, Subianto B, Fryauff DJ, McElroy PD, Leksana B, Richie TL, Masbar S, Wignall FS, Hoffman SL, 1995. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 171: 1678-1682.